Regain Biosurgery Co., Ltd.
Update：2026/11/10
Industries
Main Industry
Health Care
Main Product/Service
Innovative Composite Hemostatic Platform: This novel surgical hemostasis technology platform blends biodegradable polyurethane particles with polymers to create a composite material with diverse commercial potential. It not only accelerates wound healing but also possesses potential for anti-inflammation, anti-adhesion, and nerve repair. Depending on product requirements and objectives, the material can be formulated in different ratios for use in surgical hemostasis, anti-adhesion barriers, diabetic and burn dressings, or nerve repair products, providing multiple value-added options for surgical procedures and wound care.
GelaStop Hemostatic Matrix: The first product, GelaStop, is designed for surgeons, providing a hemostatic agent with multiple value-added functions. Applied to superficial and deep surgical hemostasis, it enables users to shorten operation times, reduce hospital stays, and lower the probability of reoperation.
GelaStop Hemostatic Matrix: The first product, GelaStop, is designed for surgeons, providing a hemostatic agent with multiple value-added functions. Applied to superficial and deep surgical hemostasis, it enables users to shorten operation times, reduce hospital stays, and lower the probability of reoperation.
The content above was translated by Ai
Founded Year
2021
Unified Business No.
90704466
Status
Active
Number of Employees
0
Total Paid-in
Capital
11,500,000 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Based on biodegradable polyurethane particles with anti-inflammatory and nerve-repairing properties, Regain Biosurgery Co., Ltd. designs and develops an innovative composite hemostatic platform with diverse commercial potential. This platform not only accelerates wound healing but also addresses common issues associated with commercially available hemostats, such as post-use compression or nerve damage, thereby providing auxiliary solutions for intraoperative hemostasis and improving postoperative adverse reactions to achieve optimal patient care.
Regain Biosurgery Co., Ltd. develops its innovative composite hemostatic platform from medical, scientific, and business perspectives to solve problems such as bleeding during surgical procedures, postoperative side effects, and wound care, with the expectation that the future launch of various products will reduce the burden on patients and further enhance medical quality and human well-being.
Regain Biosurgery Co., Ltd. is currently seeking domestic and international investment partners, as well as biotech companies or medical device manufacturers for strategic cooperation, to support subsequent human clinical trials and co-create brand-new medical products. Currently, the first product, GelaStop, is expected to obtain regulatory approval and go on sale after 2023, while other indications and corresponding product lines are also being developed simultaneously. The exit strategy includes out-licensing, co-development, and mergers and acquisitions.
Regain Biosurgery Co., Ltd. develops its innovative composite hemostatic platform from medical, scientific, and business perspectives to solve problems such as bleeding during surgical procedures, postoperative side effects, and wound care, with the expectation that the future launch of various products will reduce the burden on patients and further enhance medical quality and human well-being.
Regain Biosurgery Co., Ltd. is currently seeking domestic and international investment partners, as well as biotech companies or medical device manufacturers for strategic cooperation, to support subsequent human clinical trials and co-create brand-new medical products. Currently, the first product, GelaStop, is expected to obtain regulatory approval and go on sale after 2023, while other indications and corresponding product lines are also being developed simultaneously. The exit strategy includes out-licensing, co-development, and mergers and acquisitions.
The content above was translated by Ai
